Type 2 Diabetes
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Voluntary participation and signing of consent prior to trial; 2. Patients with type 2 diabetes, according to the WHO 1999 diagnostic criteria, who treated with premixed insulin(pen syringes) monotherapy and/or premixed insulin combined with oral antidiabetic drugs and the treatment was stable for more than three months; 3. Fasting glucose between 6.1-16 mmolL, postprandial(or random) glucose below 22.2mmol/L; 4. No acute complications such as diabetic ketoacidosis, diabetic hypertosmolar syndrome; 5. Subjects were able and willing to ues CGMS and eat regularly. Patients who were able to inject insulin themselves or actual injections can be accompanied.
Exclusion criteria
Exclusion criteria: 1. Insulin allergy; 2. The ALT of liver and kidney function was 2.5 times higher than the normal value. Serum creatinine was 1.3 times higher than the normal value; 3. There has been a history of drug abuse and alcohol dependence in the past five years, or systemic hormone therapy within 3 months; 4. Patients with poor compliance and irregular eating and exercise. Infection or stress within four weeks. Patients unable to tolerate CGMS. Pregnant, lactation or intentionally pregnant. Any other obvious condition or combination of diseases determined by the researcher: such as severe cardiopulmonary, endocrine, neurological, oncological,or a history of mental illness.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| insulin antibody; | — |
Primary
| Measure | Time frame |
|---|---|
| MAGE;HbA1C; | — |
Countries
China
Contacts
Nanjing First Hospital